Navigation Links
Engineered immune cells produce complete response in child with an aggressive pediatric leukemia
Date:12/9/2012

By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom-designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child's doctors found that she had no evidence of cancer.

Pediatric oncologist Stephan A. Grupp, M.D., Ph.D., of The Children's Hospital of Philadelphia, and colleagues from the University of Pennsylvania presented updated results of the clinical trial involving these engineered cells at the American Society of Hematology (ASH) annual meeting today in Atlanta. Grupp is the director of Translational Research for the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia, and a professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.

Grupp's research builds on his ongoing collaboration with Penn scientists who originally developed the modified T cells as a treatment for B-cell leukemias. The Penn team reported on early results of a trial using this cell therapy in adult chronic lymphocytic leukemia (CLL) patients in August of 2011. Carl H. June, M.D., of the Perelman School of Medicine at the University of Pennsylvania, leads this research group, which along with Grupp's work, is presenting new data at the ASH meeting showing that nine of 12 patients with advanced leukemias in the clinical trial, including two children, responded to treatment with CTL019 cells.

One of the nine responding patients is the 7-year-old with acute lymphoblastic leukemia (ALL). Grupp and Penn colleagues adapted the treatment to combat ALL, the most common childhood leukemia, and also the most common childhood cancer. Although physicians can cure roughly 85 percent of ALL cases, the
'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-970-3685
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Leukemia patients remain in remission more than 2 years after engineered T cell therapy
2. Bioengineered marine algae expands environments where biofuels can be produced
3. Soft Robotics: A groundbreaking new journal on engineered soft devices that Interact with Living Systems
4. Engineered bacteria can make the ultimate sacrifice
5. Ecologist: Genetically engineered algae for biofuel pose potential risks that should be studied
6. Success of engineered tissue depends on where its grown
7. Lab-engineered kidney project reaches early milestone
8. Engineered robot interacts with live fish
9. Engineered microvessels provide a 3-D test bed for human diseases
10. New research reveals challenges in genetically engineered crop regulatory process
11. Ultrasound idea: Prototype NIST/CU bioreactor evaluates engineered tissue while creating it
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/12/2015)...  New research unveiled at Black Hat 2015 ... steal users, fingerprints. Information released today by HYPR ... on mobile devices, making the security of this ... mobile devices, HYPR Corp. recently released a biometric ... with strong cryptographic security. More information on this ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... One delivers new insight about rapid toxin evolution in ... an arms race with opossums, a group of snake-eating American ... venomous snakes, this fact has not been factored into previous ... venom is usually seen as a feeding, or trophic, adaptation. ...
... Researchers from the John Theurer Cancer Center at ... studies during the recently concluded American Society of Clinical ... 7, 2011 in Chicago. The studies examined new ... and patient quality of life issues. "ASCO ...
... countries Thursday in a recommendation to regional fishery management ... unreported and unregulated (IUU) fishing for tunas, swordfish, sharks ... due to IUU fishing are estimated to be as ... first step toward procedures for sharing information about vessels ...
Cached Biology News:Rapid venom evolution in pit vipers may be defensive 2Rapid venom evolution in pit vipers may be defensive 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6US joins over 50 nations in adopting recommendation to list vessels engaged in illegal fishing 2US joins over 50 nations in adopting recommendation to list vessels engaged in illegal fishing 3
(Date:8/28/2015)... 28, 2015 According to a ... Cryogenic Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human ... Trials), End User - Global Forecast to 2020", published ... reach USD 3,731.03 Million by 2020 from USD 2,150.48 ... between 2015 and 2020. Browse 74 ...
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development ... for the quarter ended June 30, 2015, corporate ... and management report are available at www.sedar.com ... . "RepliCel expects to launch ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City Animal Health ... animal health companies to hear from animal health companies with the newest technology. ... licensing agreements or distribution contracts. This meeting is one of the only ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... DIEGO, June 4 Anadys Pharmaceuticals, Inc. (Nasdaq: ... operations on the development of ANA598, in particular a proposed ... combination with pegylated interferon-alpha and ribavirin. , ... suspend further development of ANA773 and is reducing its workforce ...
... Push of a Button , , CLEVELAND, June 4 ... the patented probiotic strain Ganeden BC30 (R), today announced a ... beverage using PowerCap(R) technology, the innovative bottle cap dispensing system. ... with the press of a button, creating a new category ...
... Roche at 69th Scientific Sessions , , SAN ... VIAP ), a biotechnology company focused on the ... metabolic disease, announced today that preclinical data related to ... presented in a poster presentation at the 69th Scientific ...
Cached Biology Technology:Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 2Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 3Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 4Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 5Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 2Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
... H- Reverse Transcriptase (RT) is an improved ... It is a DNA polymerase that synthesizes ... DNA or an RNA:DNA hybrid. This enzyme ... point mutations rather than a deletion in ...
... Reverse Transcriptase (RT) is an improved version ... is a DNA polymerase that synthesizes a ... or an RNA:DNA hybrid. This enzyme is ... mutations rather than a deletion in the ...
... Polynucleotide Kinase (PNK) catalyzes the transfer ... the 5'-hydroxyl of single- and double-stranded ... enzyme also removes the 3'-phosphate from ... 3', 5'-diphosphates to form a 3'-hydroxyl ...
Biology Products: